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T
Xbefore and after transplantation. Performing transplantation
in the patient as soon as possible, not necessarily fully recov-
ered, may be prudent. Although virtual cross-matching is
convenient, it requires further validation before replacing
prospective cross-matching in highly sensitized individuals.
Initiating MCS early with a single definitive device may im-
prove survival to and after cardiac transplantation. Early
transplant, which avoids infection, sensitization, and neuro-
logic complications, may improve bridge and transplant sur-
vival.
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Discussion
Dr J. Kirklin (Birmingham, Ala). This is an elegant and sophis-
ticated analysis that takes on a complex and controversial issue in
cardiac transplantation. As you know, Nick, we previously ana-
lyzed the information from the Cardiac Transplant Research Data-
base, and as you did at the Cleveland Clinic, we found that there
was a progressive increase in risk for the longer duration of support
before cardiac transplantation. The one difference was that we also
found an increased risk, as have some other studies, in the first 2
weeks more or less. So this is the crux of the matter in this analysis.
Many transplant centers, and in fact most now, have a general pol-
icy of more or less 30 days, if the patient is, as you say, ambulatory
and his/her subsystem dysfunction is reversed, to go ahead and acti-
vate for transplantation.So the real core of the issue of a potential con-
troversy exists in that first 3 to 4 weeks. To enlighten us and help us
analyze or perhaps judge the efficacy of yourmodel in really address-
ing that first period after the patient receives the device, 2 questions.
Many other analyses have indicated that increasing risk of dura-
tion of time on support has a major effect on the early phase of risk
after cardiac transplantation. We found that for both increase in du-
ration of support and very early transplantation. To what do you at-
tribute your finding that it was only operative in the late phase of
hazard after cardiac transplantation, which I find a little bit curious?
Second, and more important, you mention in your article that
17% of the patients actually underwent transplantation within 30
days of receiving their device. So this is the cohort of special inter-
est. Did you have the opportunity to look specifically at the patient
characteristics or profiles of that 17% who actually had a transplant
within 30 days of the device? For example, were these so-called IN-
TERMACS class I, in cardiogenic shock, did they receive ECMO
support or other short-term device, and if so, what really played in
the clinician’s mind to allocate transplantation of them early as op-
posed to switching to a more durable device? And for those who
had a durable device, what were the patient profiles? Do we have
evidence they had insufficient reversal of organ dysfunction at
the time you performed transplantation that would help supportdiovascular Surgery c Volume 139, Number 5 1303
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reversal of organ dysfunction?
Dr Smedira. Thanks, Jim, for your comments, and I would first
like to take this opportunity to recognize Dr Kirklin for his contri-
butions, both the transplant database and nowwith the development
of the INTERMACS registry, which I think will help enlighten us
and answer some of these questions. Let me answer 2 first and then
go back and speculate on the first question.
Seventeen percent of our patients underwent transplantation
within 4 weeks. Nine of our patients underwent transplantation
off of ECMO or the BVS 5000 system (ABIOMED, Inc, Danvers,
Mass). We could not find anything that distinguished those cohorts
receiving transplants early or late. There were no distinguishing
characteristics. I think it was the philosophy of the surgeons that
this person was best served by going straight to transplantation.
That is a surprise to me, because even within my own institution
I didn’t think we were doing that, but in fact my colleagues were,
and the results weren’t bad.
As for implantable devices, as I said, I used to hold the bar up to
15minutes on the treadmill before I would activate a patient. Again,
my colleagues would go sooner. And so I think the way I put this
together is if the patient has recovered organ function, is ambula-
tory and doing well, there is really no contraindication to proceed
with transplantation. It was difficult to define anything unique
about these early transplant recipients.
Now, why do they have a decrement at 3 to 5 years? I looked
closely at your article in the Journal, and you showed there was
a relative risk of approximately 1.46 in those undergoing transplan-
tation after 6 months, if I remember correctly, and you said your
early phase went from 30 days to 2 years. Now, my best guess is
it is probably some immune-mediated problem related to the de-
vice. Now, most of our patients had HeartMate devices, and we
had some Novacor devices (World Heart Inc, Salt Lake City,
Utah), and there is a great deal of information about the device sur-
face activating the immune system. So my best guess for why this
would be showing up at the 2- to 3-year mark is some immune ac-
tivation. We saw that it was much worse in the patients who were
infected and sensitized, and we know those patients are immune-
activated. So I think it is a synergistic activation of those factors.
Dr J. Conte (Baltimore, Md). Nick, a very nice presentation, but
as I was sitting here listening, I am really not sure what the take-
home message is. My current practice is to put the ventricular assist
device in; the patient recovers, is discharged, and returns to the
clinic every week thereafter; and once the patient mentally and
physically feels good, and the laboratory values are good, we think
the patient has recovered. If the patient is walking around, doing
well at home, then we list him/her for transplantation. A couple
of years ago that is what UNOS told us was appropriate for us to
now begin the patient’s status 1a time. Once the transplant team
thought the patient was ready for transplant, we could go ahead
and list him/her.
If you have a patient who is doing well after ventricular assist de-
vice implantation, at what point exactly are you saying we ought to
perform transplantation in these patients? Because we may be do-
ing the same thing. I am not really sure what you are doing, but
could you be specific about that?
Dr Smedira. Let me address the first part of that. What we saw
in these patients who are discharged, brought back, and are doing1304 The Journal of Thoracic and Cardiovascular Surfine and everything is looking good, is that we lose patients as
we wait for them to become perfect candidates. We have had pa-
tients whom we wanted to recover a bit and learn a bit more how
to deal with their device, and they have died of strokes before we
were able to activate them. Any of you in the business has seen
the recent notifications of HeartMate II outflow cannula disconnect
where the patient died. We had a recent patient who just required an
emergency operation because fluid was aspirated in the vent. My
impression is the longer you keep patients on the device, you run
the risk of device and patient interaction and malfunction, and
you will lose some patients. When the patient is, to your best esti-
mate, ready to undergo another operation, he/she should be acti-
vated for transplantation with the bar not set excessively high.
DrConte. I think I agree with you, but what time are you saying?
Dr Smedira. Our study says it doesn’t matter. And I know my
colleague, Dr Banbury, is here, and if he saw the patient was sitting
up and could move around, it is time to undergo transplantation.
Could be 2 weeks, 7 days, 10 days, a different approach. In our
analysis, going in early, within 4 weeks, did not affect survival.
Dr Conte. The paradigm that most people have is an LVAD is
implanted; they recover. Yours is a little bit different.
Dr Smedira. That has always been our paradigm, the patient re-
covery. The question is, is that the smartest and safest thing to do?
What we showed is we don’t have any negative impact by perform-
ing transplantation in patients as soon as they seem ready for it.
Dr Conte. I guess what I was looking for was more of a black
and white.
Dr Smedira. There is no black and white.
Dr L. von Segesser (Lausanne, Switzerland). When you list
a patient, how much waiting time is there?
Dr Smedira. For these patients, our median support time was
2.7 months, and for our transplant recipients, our median wait
time is 2.4 months.
Dr Von Segesser. So if you say you decided a patient was ready
now, he would have to wait how long?
Dr Smedira. A couple of weeks at most.
Dr P. Portner (Stanford, Calif). I enjoyed your presentation,
Nick. It was very interesting. I am trying to understand exactly
what you said, but you are not suggesting that in your practice,
or your combined practice, that you in fact keep patients on devices
just because they are doing well beyond the time that you could in
fact list them, and then the time to transplant is in fact whatever it
takes to receive a donor? Because there are some people who have
been suggesting that having a patient with no morbidity, extend that
period of time, although you have an ongoing potential risk, ex-
tends the time that you give them when you add that to the trans-
plantation.
Dr Smedira. I had believed in that philosophy, but now I think
that from our data we would suggest that you lose more patients by
doing that than by moving forward to transplant as soon as they are
ready.
Dr Portner. At the end of the day, though, it is a subjective de-
cision as to when you list them, right?
Dr Smedira. Yes, it always is. It is a clinical decision trying to
balance the risk of going to transplantation at this time and the risk
of events occurring on the device.
Dr Portner. In your earlier response to Jim Kirklin, with the 17
patients you have analyzed in the first month, are you suggestinggery c May 2010
Smedira et al Cardiothoracic Transplantationthat you wouldn’t even wait for that early postoperative, potentially
morbid period? You would go ahead and list them immediately or
you still have some time that you would allow for early recovery?
Dr Smedira. It depends on what the recovery is. If you have
somebody with an acute myocardial infarction, cardiogenic shock,
you put an LVAD in and 5 days later he has a creatinine of 1, he isThe Journal of Thoracic and Carsitting up, eating food, and watching the Ohio State football game,
that guy is ready for transplantation, and it has only been 9 days, but
in the past I would say, well, he has to be on the treadmill. But this
guy wasn’t ill 5 days ago and he has now recovered from an un-
eventful VAD. You move forward with the transplantation with 9
days of support.diovascular Surgery c Volume 139, Number 5 1305
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